^
    8ms
    A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, AstraZeneca | Trial completion date: Feb 2025 --> Nov 2024 | Trial primary completion date: Feb 2025 --> Nov 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • MEDI9253
    1year
    A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=86 --> 37 | Trial completion date: Nov 2025 --> Feb 2025 | Trial primary completion date: Nov 2025 --> Feb 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • MEDI9253
    over3years
    A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors (clinicaltrials.gov)
    P1, N=86, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Jun 2025 --> Nov 2025
    Clinical • Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • MEDI9253
    over3years
    A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors (clinicaltrials.gov)
    P1, N=86, Not yet recruiting, AstraZeneca
    Clinical • New P1 trial • Combination therapy
    |
    CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • MEDI9253